LACTOLOGY FOUNDATION

Here is an English, web‑page style toxico‑lactation monograph for medicines in ATC class A06AD18 (sorbitol), followed by meta description and meta keywords as requested.

Definition and ATC class

Medicines in ATC class A06AD18 contain sorbitol, a sugar alcohol with osmotic laxative properties used orally and rectally for the relief of constipation and to facilitate bowel evacuation.medpedia.framar+2
Sorbitol also occurs naturally in many fruits (for example apples, pears and plums) and is widely used as a pharmaceutical excipient and sweetener in oral liquid preparations, chewable tablets, lozenges and dental care products.pharmaexcipients+2

Pharmacodynamics

As an osmotic laxative, sorbitol retains water within the colon lumen, increases the volume and softens the stool, thereby stimulating peristalsis and facilitating defecation.drugbank+1
At higher doses, the non‑absorbed fraction of sorbitol produces marked osmotic fluid shifts and accelerates colonic transit, which explains its dose‑dependent tendency to cause diarrhea and abdominal cramping.news-medical+1

Pharmacokinetics

Sorbitol is slowly absorbed from the gastrointestinal tract and is partially metabolised to fructose and glucose, entering the polyol pathway and contributing to energy production.wikipedia+1
A substantial portion remains non‑absorbed in the small intestine and reaches the colon where it exerts its laxative effect; systemic exposure is therefore limited at standard laxative doses, although accumulation in sensitive patients may occur with chronic high intake.news-medical+1

Indications and clinical use

Medicinal products containing sorbitol in class A06AD18 are indicated for short‑term treatment of constipation, for bowel emptying prior to diagnostic procedures, and as components of enemas or oral solutions with laxative action.medpedia.framar+1
Outside strictly laxative use, sorbitol is also utilised as a sweetener and stabiliser in numerous oral pharmaceutical formulations, but these excipient roles generally involve lower doses than dedicated osmotic laxatives.pubmed.ncbi.nlm.nih+1

Adverse effects and toxicity

Common adverse reactions to sorbitol laxatives include abdominal pain, flatulence, bloating and mild to severe diarrhea with potential fluid loss and electrolyte imbalance, especially at doses above individual tolerance.medpedia.framar+1
Excessive sorbitol intake has been associated with gastrointestinal disturbances, and in highly sensitive patients may lead to more serious symptoms such as marked diarrhea, cramping, and, rarely, systemic complaints including breathlessness or cutaneous itching.news-medical+1

Drug interactions and excipient‑related effects

Interaction databases list clinically significant interactions between sorbitol and multiple drugs; sorbitol‑containing solutions can reduce the oral bioavailability of certain BCS class II and III medicines, such as risperidone, lamivudine and ranitidine, by altering intestinal transit and dissolution.pubmed.ncbi.nlm.nih+1
For other drugs, including cimetidine and acyclovir, sorbitol did not meaningfully change pharmacokinetic profiles, so interaction relevance is formulation‑ and drug‑specific and should be checked in dedicated interaction resources.pubmed.ncbi.nlm.nih+1

Special populations: pregnancy

Human data on sorbitol use in pregnancy are limited, and sorbitol has not been assigned a formal FDA pregnancy risk category; it should therefore be used during pregnancy only when the expected benefit outweighs potential risks.drugs+1
Available toxicological information does not indicate carcinogenicity, and regulatory agencies classify sorbitol as generally safe at typical dietary or medicinal exposures, but high doses may aggravate gastrointestinal symptoms in pregnant women and warrant medical supervision.drugs+1

Special populations: lactation

There are no direct quantitative data on sorbitol excretion into human breast milk, and most sources state that sorbitol is not expected to be present in breast milk in clinically relevant concentrations.e-lactation+1
Sugar alcohols and polyols are generally considered compatible with breastfeeding when consumed at usual dietary levels, and sorbitol‑containing medicines are usually regarded as low‑risk for healthy term infants, although maternal overuse may provoke maternal diarrhea and dehydration, indirectly affecting breastfeeding.lacted+2

Experimental data on lactation and offspring

Experimental animal studies of maternal sorbitol exposure during lactation have reported dose‑dependent metabolic alterations and genotoxic responses in offspring, including changes in liver enzymes, lipid profile, and evidence of hepatocyte and blood‑cell DNA damage.pubmed.ncbi.nlm.nih
These findings suggest that very high experimental doses can provoke systemic toxicity in suckling animals, but the relevance to human lactation at therapeutic laxative doses remains uncertain, and current clinical guidance continues to classify sorbitol as relatively safe or compatible with breastfeeding when used appropriately.pubmed.ncbi.nlm.nih+2

Clinical recommendations in breastfeeding women

When sorbitol‑containing laxatives are required during breastfeeding, short‑term use at the lowest effective dose is advisable, with monitoring for maternal gastrointestinal side effects and infant stool pattern.e-lactation+1
In mothers or infants with pre‑existing gastrointestinal disease or in premature or medically fragile infants, non‑pharmacological constipation measures or alternative laxatives with better characterised lactation data may be preferred, and individual risk–benefit assessment by a healthcare professional is recommended.mayoclinic+1

Risk assessment and safety profile

Regulatory and toxicological evaluations classify sorbitol as safe for use in foods and medicines, with an acceptable daily intake “not specified,” indicating low concern at typical exposure levels, although doses above approximately 30–50 g per day can induce significant diarrhea in adults.news-medical
From a toxico‑lactological perspective, sorbitol in A06AD18 medicinal products is considered low‑risk for breastfeeding when used intermittently at therapeutic doses, but large or chronic exposures may justify caution due to potential maternal gastrointestinal disturbances and limited human lactation pharmacokinetic data.lacted+2